Journal of International Oncology››2015,Vol. 42››Issue (12): 896-899.doi:10.3760/cma.j.issn.1673-422X.2015.12.004
Previous ArticlesNext Articles
Liu Xuefei, Li Wenhui, Xin Yan
Online:
2015-12-08Published:
2015-11-10Contact:
Xin Yan E-mail:yxin@mail.cmu.edu.cnLiu Xuefei, Li Wenhui, Xin Yan. Clinicopathological significance and expression of Numb and α-catenin in gastric carcinoma[J]. Journal of International Oncology, 2015, 42(12): 896-899.
[1] Herrero R, Park JY, Forman D. The fight against gastric cancer—the IARC Working Group report[J]. Best Pract Res Clin Gastroenterol, 2014, 28(6): 1107-1114. [2] Gulino A, Di Marcotullio L, Screpanti I. The multiple functions of Numb[J]. Exp Cell Res, 2010, 316(6): 900-906. [3] Wang Z, Li SS. Numb: a new player in EMT[J]. Cell Adh Migr, 2010, 4(2): 176-179. [4] Troyanovsky RB, Klingelhfer J, Troyanovsky SM. αCatenin contributes to the strength of Ecadherinp120 interactions[J]. Mol Biol Cell, 2011, 22(22): 4247-4255. [5] Yan B. Numb—from flies to humans[J]. Brain Dev, 2010, 32(4): 293-298. [6] Dhami GK, Liu H, Galka M, et al. Dynamic methylation of Numb by Set8 regulates its binding to p53 and apoptosis[J]. Mol Cell, 2013, 50(4): 565-576. [7] Wang C, Cui T, Feng W, et al. Role of numb expression and nuclear translocation in endometrial cancer[J]. Oncol Lett, 2015, 9(4): 1531-1536. [8] Hong J, Liu Z, Zhu H, et al. The tumor suppressive role of NUMB isoform 1 in esophageal squamous cell carcinoma[J]. Oncotarget, 2014, 5(14): 5602-5614. [9] Sato K, Watanabe T, Wang S, et al. Numb controls Ecadherin endocytosis through p120 catenin with aPKC[J]. Mol Biol Cell, 2011, 22(17): 3103-3119. [10] Zhao C, Guo H, Li J, et al. Numb family proteins are essential for cardiac morphogenesis and progenitor differentiation[J]. Development, 2014, 141(2): 281-295. [11] Greer RL, Staley BK, Liou A, et al. Numb regulates acinar cell dedifferentiation and survival during pancreatic damage and acinartoductal metaplasia[J]. Gastroenterology, 2013, 145(5): 1088-1097.e8. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[7] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[8] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[9] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[10] | Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang.Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion[J]. Journal of International Oncology, 2023, 50(2): 71-75. |
[11] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[12] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[13] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[14] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[15] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||